In vitro interactions between aged garlic extract and drugs used for the treatment of cardiovascular and diabetic patients

European Journal of Nutrition

Volumn 49, Issue 6, 2010, Pages 373-384

  Berginc, Katja ^a   Žakelj, Simon ^a   Kristl, Albin ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Aged garlic extract; Caco 2 cell monolayers; Drugs; Interactions; Intestinal transporters; Rat intestine

Indexed keywords

ATENOLOL; ATORVASTATIN; BREAST CANCER RESISTANCE PROTEIN; CIPROFLOXACIN; DIGOXIN; FUROSEMIDE; GARLIC EXTRACT; GLIBENCLAMIDE; GLIPIZIDE; GLYCOPROTEIN P; HYDROCHLOROTHIAZIDE; LOSARTAN; MONOCARBOXYLATE TRANSPORTER 1; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER; PEPTIDE TRANSPORTER 1; PRAVASTATIN; PRAZOSIN; RHODAMINE 123; ROSUVASTATIN; SILDENAFIL; VALACICLOVIR; VALSARTAN;

ANIMAL CELL; ARTICLE; CARDIOVASCULAR DISEASE; CELL STRAIN CACO 2; CONTROLLED STUDY; DIABETES MELLITUS; DIFFUSION CHAMBER; DRUG ABSORPTION; DRUG TRANSPORT; HUMAN; HUMAN CELL; ILEUM; INTESTINE ABSORPTION; INTESTINE CELL; MEMBRANE PERMEABILITY; NONHUMAN;

ANIMALS; CACO-2 CELLS; CARDIOVASCULAR AGENTS; CELL MEMBRANE PERMEABILITY; DIETARY SUPPLEMENTS; FOOD-DRUG INTERACTIONS; GARLIC; HUMANS; HYPOGLYCEMIC AGENTS; INTESTINAL ABSORPTION; INTESTINE, SMALL; MALE; MONOCARBOXYLIC ACID TRANSPORTERS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; PLANT EXTRACTS; PLANT ROOTS; RATS; RATS, WISTAR; SYMPORTERS; TRANSCYTOSIS;

ALLIUM SATIVUM; RATTUS;

EID: 77955851957     PISSN: 14366207     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00394-010-0095-x     Document Type: Article

References (46)

1. RS Rivlin 2001 Historical perspective on the use of garlic J Nutr 131 3S 951S 954S 1:CAS:528:DC%2BD3MXhvVOitbs%3D
2. KC Agarwal 1996 Therapeutic actions of garlic constituents Med Res Rev 16 111 124 10.1002/(SICI)1098-1128(199601)16:1<111::AID-MED4>3.0.CO;2-5 1:CAS:528:DyaK28XhtFyls7o%3D (Pubitemid 26037077)
3. S Ejaz LC Woong A Ejaz 2003 Extract of garlic (Allium Sativum) in cancer chemoprevention Exp Oncol 25 93 97 1:CAS:528:DC%2BD3sXntVSrtrg%3D
4. YY Yeh L Liu 2001 Cholesterol-lowering effect of garlic extracts and organosulfur compounds: human and animal studies J Nutr 131 3S 989S 993S 1:CAS:528:DC%2BD3MXhvVOiur0%3D
5. H Amagase 2006 Clarifying the real bioactive constituents of garlic J Nutr 136 716S 725S 1:CAS:528:DC%2BD28XitFCmtrw%3D
6. A Fugh-Berman 2000 Herb-drug interactions Lancet 355 134 138 10.1016/S0140-6736(99)06457-0 1:CAS:528:DC%2BD3cXptleluw%3D%3D
7. CY Wu LZ Benet 2005 Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutical drug disposition classification system Pharm Res 22 11 23 10.1007/s11095-004-9004-4 1:CAS:528:DC%2BD2MXhtlCks70%3D (Pubitemid 40558141)
8. S Deferme P Augustijns 2003 The effect of food components on the absorption of Pgp substrates: a review J Pharm Pharmacol 55 153 162 10.1211/002235702603 1:CAS:528:DC%2BD3sXisVOjs7c%3D (Pubitemid 36277751)
9. B Foster M Foster S Vandenhoek A Krantis JW Budzinski JT Arnason KD Gallicano S Choudri 2001 An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic J Pharm Pharmaceut Sci 4 176 184 1:CAS:528:DC%2BD3MXnsFyhtLk%3D
10. Lancaster JE, Boland MJ (1989) Flavor Biochem. In: Brewster JL, Rabinowitch HD (eds) Onions and allied crops: food science and minor crops. CRC Press, USA, pp 34-54
11. MG Jones J Hughes A Tregova J Milne AB Tomsett HA Collin 2004 Biosynthesis of the flavour precursors of onion and garlic J Exp Bot 55 1903 1918 10.1093/jxb/erh138 1:CAS:528:DC%2BD2cXntFaisbc%3D (Pubitemid 39123323)
12. Holub BJ, Arnott K, Davis JP, Nagpurkar A, Peschell J (2002) Organosulfur compounds from garlic. In: Shi J, Mazza G, Maguer M (eds) Functional foods, biochemical and processing aspects. CRC Press, USA, pp 214-231
13. K Berginc D Uršič S Žakelj A Kristl 2009 Aged garlic extract stimulates P-glycoprotein and multidrug resistance associated protein 2 mediated effluxes Biol Pharm Bull 32 694 699 10.1248/bpb.32.694 1:CAS:528:DC%2BD1MXmsVSksLc%3D
14. RT Rosen RD Hiserodt EK Fukuda RJ Ruiz Z Zhou J Lech SL Rosen TG Hartman 2001 Determination of allicin, S-allylcysteine and volatile metabolites of garlic in breath, plasma or simulated gastric fluids J Nutr 131 3S 968S 971S 1:CAS:528:DC%2BD3MXhvVOitbY%3D
15. H Amagase BL Petesch H Matsuura S Kasuga 2001 Intake of garlic and its bioactive components J Nutr 131 S3 955S 962S 1:CAS:528:DC%2BD3MXhvVOitbg%3D
16. AB Shapiro V Ling 1997 Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities Eur J Biochem 250 130 137 10.1111/j.1432-1033.1997.00130.x 1:CAS:528:DyaK2sXnslGgt7o%3D
17. DK Yu 1999 The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions J Clin Pharmacol 39 1203 1211 10.1177/00912709922012006 1:CAS:528:DC%2BD3cXisVaktA%3D%3D
18. YH Zhao MH Abraham J Le A Hersey CN Luscombe G Beck B Sherborne I Cooper 2002 Rate-limiting steps of human oral absorption and QSAR studies Pharm Res 19 1446 1457 10.1023/A:1020444330011 1:CAS:528:DC%2BD38XnsFSgsb8%3D (Pubitemid 35266548)
19. SF Su JD Huang 1996 Inhibition of intestinal digoxin absorption and exsorption by quinidine Drug Metab Dispos 24 142 147 1:CAS:528: DyaK28XhtFCrsrg%3D
20. A Soldner LZ Benet E Mutschler U Christians 2000 Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and Caco-2 cell monolayers Br J Pharmacol 129 1235 1243 10.1038/sj.bjp.0703150 1:CAS:528:DC%2BD3cXit1egsL4%3D
21. W Yamashiro K Maeda M Hirouchi Y Adachi Z Hu Y Sugiyama 2006 Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptors in humans Drug Metab Dispos 34 1247 1254 10.1124/dmd.105.008938 1:CAS:528:DC%2BD28XmsVKqsbw%3D
22. E Bakos R Evers E Sinko A Varadi P Borst B Sarkadi 2000 Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions Mol Pharmacol 57 760 768 1:CAS:528:DC%2BD3cXit1ehurk%3D
23. E Wang CN Casciano RP Clement WW Johnson 2001 HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein Pharm Res 18 800 806 10.1023/A:1011036428972 1:CAS:528:DC%2BD3MXlt1Cqtbk%3D (Pubitemid 32783516)
24. MVS Varma K Sateesh R Panchagnula 2004 Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport Mol Pharm 2 12 21 10.1021/mp0499196
25. MJ Zamek-Gliszczynski KA Hoffmaster JE Humphreys X Tian K Nezasa KLR Brouwer 2006 Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulphate in the rat JPET 319 459 467 10.1124/jpet.106.101840 1:CAS:528:DC%2BD28XhtVCksLjN (Pubitemid 44455153)
26. S Žakelj K Šturm A Kristl 2006 Ciprofloxacin permeability and its active secretion through rat small intestine in vitro Int J Pharm 313 175 180 10.1016/j.ijpharm.2006.02.004
27. Guidance for industry bioavailability and bioequivalence studies for orally administered drug products - general considerations. Food and Drug Administration, Center for Drug evaluation and Research (CDER). Available via DIALOG http://www.fda.gov/cder/guidance/index.htm
28. C Maclean U Moenning A Reichel G Fricker 2008 Closing the gaps-A full scan of the intestinal expression of Pgp, Bcrp and Mrp2 in male and female rats Drug Metab Dispos 36 1249 1254 10.1124/dmd.108.020859 1:CAS:528: DC%2BD1cXotVegurk%3D (Pubitemid 351929307)
29. E Lee S Ryan B Birmingam J Zalikowski R March H Ambrose R Moore C Lee Y Chen 2005 Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment Clin Pharmacol Ther 78 330 341 10.1016/j.clpt.2005.06.013 1:CAS:528:DC%2BD2MXhtVGrsLfF (Pubitemid 41393668)
30. B Steffansen CU Nielsen B Brodin AH Eriksson R Andersen S Frokjaer 2004 Intestinal solute carriers: an overview of trends and strategies for improving oral drug absorption Eur J Pharm Sci 21 3 16 10.1016/j.ejps.2003.10.010 1:CAS:528:DC%2BD2cXovFSn (Pubitemid 38050200)
31. TN Faria JK Timoszyk TR Stouch BS Vig CP Landowski GL Amidon CD Weaver DA Wall RL Smith 2003 A novel high-throughput Pept1 transporter assay differentiates between substrates and antagonists Mol Pharm 1 67 76 10.1021/mp034001k
32. KT Kivistö M Niemi 2007 Influence of drug transporter polimorphism on pravastatin pharmacokinetics in humans Pharm Res 24 239 247 10.1007/s11095-006-9159-2 (Pubitemid 46072183)
33. T Katsura KI Inui 2003 Intestinal absorption of drugs mediated by drug transporters: mechanisms and regulation Drug Metab Pharmacokinet 18 1 15 10.2133/dmpk.18.1 1:CAS:528:DC%2BD3sXks1yrsrs%3D
34. X Sha G Yan Y Wu J Li X Fang 2005 Effect of self-emulsifying drug delivery systems containing Labrasol on tight junctions in Caco-2 cells Eur J Pharm Sci 24 477 486 10.1016/j.ejps.2005.01.001 1:CAS:528:DC%2BD2MXisFGksbc%3D (Pubitemid 40387261)
35. K Rahman GM Lowe 2006 Garlic and cardiovascular disease: a critical review J Nutr 136 3 736S 740S 1:CAS:528:DC%2BD28XitFCmtrs%3D
36. G Flesch PL Muller 1997 Absolute bioavailability and pharmacokinetics of valsaratn, an angiotensin II receptor antagonist, in man Eur J Clin Pharmacol 52 115 120 10.1007/s002280050259 1:CAS:528:DyaK2sXjsVCgu7w%3D (Pubitemid 27239595)
37. MW Lo MR Goldberg JB McCrea H Lu C Furtek TD Bjornsson 1995 Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans Clin Pharmacol Ther 58 641 649 10.1016/0009-9236(95)90020-9 1:CAS:528:DyaK28XhtVOgs7g%3D (Pubitemid 26018849)
38. B Ebert A Seidel A Lampen 2005 Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists Carcinogenesis 26 1754 1763 10.1093/carcin/bgi139 1:CAS:528:DC%2BD2MXhtVWnt7fN (Pubitemid 41487991)
39. A Heimeur G Conseil RG Deeley SPC Cole 2004 The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation Current drug metabolism 5 21 53 10.2174/1389200043489199 (Pubitemid 38294344)
40. L Huang Y Wang S Grimm 2006 ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein Drug Metab Dispos 34 738 743 10.1124/dmd.105.007534 1:CAS:528:DC%2BD28Xks1Sks7c%3D
41. B Masereel L Pochet D Laeckmann 2003 An overview of inhibitors of Na/H exchanger Eur J Med Chem 38 547 554 10.1016/S0223-5234(03)00100-4 1:CAS:528:DC%2BD3sXkvVGqsrg%3D (Pubitemid 36773859)
42. P Anderle Y Huang W Sadee 2004 Intestinal membrane transport of drugs and nutrients: genomics of membrane transporters using expression microarrays Eur J Pharm Sci 21 17 24 10.1016/S0928-0987(03)00169-6 1:CAS:528:DC%2BD2cXovFSl (Pubitemid 38050201)
43. N Gupta PM Martin S Miyauchi S Ananth AV Herdman RG Martindale R Podolsky V Ganapathy 2006 Down-regulation of BCRP/ABCG2 in colorectal and cervical cancer BBRC 343 571 577 1:CAS:528:DC%2BD28XivV2ku74%3D
44. HS Shin SK Bae MG Lee 2006 Pharmacokinetics of sildenafil after intravenous and oral administration of rats: hepatic and intestinal first-pass effects Int J Pharm 320 64 70 10.1016/j.ijpharm.2006.04.005 1:CAS:528: DC%2BD28XnsFCquro%3D (Pubitemid 44128707)
45. AP Halestrap D Meredith 2004 The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond Pflugers Arch 447 5 619 628 10.1007/s00424-003-1067-2 1:CAS:528:DC%2BD2cXhtVygsL4%3D (Pubitemid 38241446)
46. RK Gill S Saksena WA Alrefai Z Sarwar JL Goldstein RE Carroll K Ramaswamy PK Dudeja 2005 Expression and membrane localization of MCT isoforms along the length of human intestine Am J Physiol Cell Physiol 289 C846 C852 10.1152/ajpcell.00112.2005 1:CAS:528:DC%2BD2MXhtFens7jN (Pubitemid 41361640)